{"title":"重症监护病房的肾脏替代疗法:从保守到限制性策略","authors":"Khalil Chaïbi, Didier Dreyfuss, Stéphane Gaudry","doi":"10.1186/s13054-025-05271-4","DOIUrl":null,"url":null,"abstract":"<p>Renal replacement therapy (RRT) is a cornerstone of the management of severe acute kidney injury (AKI) in critically ill patients. Despite being life-saving in several instances, RRT may be associated with significant complications, including bleeding, hemodynamic instability, infections, thrombosis, and possibly delayed renal recovery. Large randomized controlled trials (RCTs) have demonstrated that delaying RRT initiation, in the absence of life-threatening complications (conservative RRT strategy) allows 38% to 49% of patients to avoid RRT. In addition to reducing unnecessary treatment, this conservative approach may help protect kidney function [1,2,3]. Once RRT is initiated, intensivists usually prescribe a recommended (or standard) dose of RRT (a KT/V of 3.9 per week when using intermittent hemodialysis or extended RRT; an effluent volume of 20–25 ml/kg/h for continuous RRT) [4]. This ensures the efficacy of metabolic control but there remains significant uncertainty about how long RRT should be continued. In daily clinical practice, empirical criteria (i.e. increased urine output or decreased blood urea nitrogen) are used to guide RRT weaning. Current guidelines offer indeed little guidance on how to manage this process.</p><p>Given the safety of a conservative RRT initiation strategy, we suggest extending this concept to a new approach (called restrictive RRT strategy) that could potentially solve the hot topic questions of RRT dosing and RRT weaning. This approach would consist in the suspension of RRT after 3 days. At this moment, metabolic abnormalities that mandated RRT initiation would no longer be present and the cause of AKI would be, in most cases, treated (for instance by controlling sepsis or hemorrhage). Then the question would be the same as before the initiation of the first RRT session i.e., does the situation require starting RRT or can it be delayed until a conservative RRT initiation criterion is observed again? If RRT is resumed, the patient will receive a new RRT session, after which RRT will again be suspended. This targeted approach applied until renal recovery-would ensure the use of RRT only when truly necessary rather than its prolongation for vague reasons. The restrictive strategy differs from ongoing studies that investigate the intensity of each RRT session (only for continuous RRT modality) (NCT06446739, NCT06014801, NCT06021288). Indeed, a restrictive approach would not diminish the intensity of each session, well the contrary, but the number of sessions by suspending pending a new indication for resumption occurs. Although this approach presents methodological challenges, we believe it is essential to evaluate it regardless of the initial RRT modality—intermittent (IHD) or continuous (CRRT)—since neither has shown definitive superiority.</p><p>The potential benefits of a restrictive RRT strategy for patients are numerous. By reducing unnecessary RRT exposure, patients could experience fewer episodes of hemodynamic instability, a common complication during RRT sessions, and a lower risk of infections, particularly those related to RRT catheters. Additionally, minimizing RRT may promote faster renal recovery by avoiding the \"second hit\" that RRT can impose on the kidneys [1, 5]. Fewer RRT sessions would make general patient management such as physiotherapy or transport easier. Patients might also experience better sleep quality, as RRT machines and alarms are a frequent source of disturbances improving the overall ICU environment. Moreover, RRT is a resource-intensive procedure, and minimizing its use would reduce both costs and the carbon footprint of critical care, in an era of increasing attention to healthcare sustainability [6].</p><p>On the other hand, shortening RRT sessions often raises concerns about achieving an adequate dose. Yet more intensive therapy does not necessarily translate into better outcomes in the ICU. Large RCTs have shown no mortality advantage for high-dose RRT regimens [7, 8], and recent meta-analyses even suggest that higher-intensity therapy may delay renal recovery [9]. Notably, the three above mentioned ongoing trials of low-dose CRRT demonstrate that the concept of a lower-dose intervention is considered sufficiently acceptable to be rigorously tested—thus challenging the assumption that less intensive dialysis automatically means unsafe underdialysis. However, these trials still focus on fixed-dose CRRT rather than a truly individualized approach and do not aim at reducing the number of sessions nor determining the moment for cessation. By contrast, by centering on individual patient needs, the restrictive strategy we propose aligns more closely with the ultimate goal of personalized medicine—an essential objective in modern critical care.</p><p>As we reconsider how to best use RRT, a more selective, needs-based approach could be the key to optimizing care. We are currently applying for a grant from the French Ministry of Health to conduct an RCT to evaluate this restrictive RRT strategy, focusing on a tailored approach providing no more than what is warranted.</p><p>No datasets were generated or analysed during the current study.</p><dl><dt style=\"min-width:50px;\"><dfn>RRT:</dfn></dt><dd>\n<p>Renal replacement therapy</p>\n</dd><dt style=\"min-width:50px;\"><dfn>AKI:</dfn></dt><dd>\n<p>Acute kidney injury</p>\n</dd><dt style=\"min-width:50px;\"><dfn>RCT:</dfn></dt><dd>\n<p>Randomized controlled trials</p>\n</dd></dl><ol data-track-component=\"outbound reference\" data-track-context=\"references section\"><li data-counter=\"1.\"><p>Benichou N, Gaudry S, Dreyfuss D. The artificial kidney induces acute kidney injury: yes. Intensive Care Med. 2020;46(3):513–5.</p><p>Article CAS PubMed Google Scholar </p></li><li data-counter=\"2.\"><p>STARRT-AKI Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Canadian Nephrology Trials Network, Irish Critical Care Trials Group, et al. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med. 2020;383:240–51.</p></li><li data-counter=\"3.\"><p>Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375:122–33.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\"4.\"><p>Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–84.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\"5.\"><p>Vanmassenhove J, Kielstein J, Jörres A, Biesen WV. Management of patients at risk of acute kidney injury. Lancet. 2017;389:2139–51.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\"6.\"><p>Stigant CE, Barraclough KA, Harber M, Kanagasundaram NS, Malik C, Jha V, et al. Our shared responsibility: the urgent necessity of global environmentally sustainable kidney care. Kidney Int. 2023;104:12–5.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\"7.\"><p>Network TVARFT. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20.</p><p>Article Google Scholar </p></li><li data-counter=\"8.\"><p>RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009;361:1627–38.</p><p>Article Google Scholar </p></li><li data-counter=\"9.\"><p>Wang Y, Gallagher M, Li Q, Lo S, Cass A, Finfer S, et al. Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: a systematic review and individual patient data meta-analysis. Nephrol Dial Transplant. 2018;33:1017–24.</p><p>PubMed Google Scholar </p></li></ol><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><p>Not applicable</p><p>Not applicable.</p><span>Author notes</span><ol><li><p>Stéphane Gaudry</p><p>Present address: Intensive Care Unit, Hôpital Avicenne, 125 Rue de Stalingrad, 93000, Bobigny, France</p></li></ol><h3>Authors and Affiliations</h3><ol><li><p>Département de Réanimation Médico-Chirurgicale, APHP Hôpital Avicenne, 125 Rue de Stalingrad, 93000, Bobigny, France</p><p>Khalil Chaïbi & Stéphane Gaudry</p></li><li><p>Common and Rare Kidney Diseases: from Molecular Events to Precision Medicine, CoRaKiD, Sorbonne Université, INSERM, 75020, Paris, France</p><p>Khalil Chaïbi, Didier Dreyfuss & Stéphane Gaudry</p></li><li><p>Médecine Intensive-Réanimation, APHP, Hôpital Louis Mourier, Université Paris Cité, Colombes, France</p><p>Didier Dreyfuss</p></li><li><p>Health Care Simulation Center, UFR SMBH, Université Sorbonne Paris Nord, Bobigny, France</p><p>Stéphane Gaudry</p></li></ol><span>Authors</span><ol><li><span>Khalil Chaïbi</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Didier Dreyfuss</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Stéphane Gaudry</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Contributions</h3><p>KC, DD and SG drafted the manuscript.</p><h3>Corresponding author</h3><p>Correspondence to Stéphane Gaudry.</p><h3>Ethics approval and consent to participate</h3>\n<p>Not applicable.</p>\n<h3>Consent for publication</h3>\n<p>Not applicable.</p>\n<h3>Competing interests</h3>\n<p>The authors declare no competing interests.</p><h3>Publisher's Note</h3><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p><p><b>Open Access</b> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.</p>\n<p>Reprints and permissions</p><img alt=\"Check for updates. Verify currency and authenticity via CrossMark\" height=\"81\" loading=\"lazy\" src=\"data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\" width=\"57\"/><h3>Cite this article</h3><p>Chaïbi, K., Dreyfuss, D. & Gaudry, S. Renal replacement therapy in ICU: from conservative to restrictive strategy. <i>Crit Care</i> <b>29</b>, 40 (2025). https://doi.org/10.1186/s13054-025-05271-4</p><p>Download citation<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><ul data-test=\"publication-history\"><li><p>Received<span>: </span><span><time datetime=\"2024-11-26\">26 November 2024</time></span></p></li><li><p>Accepted<span>: </span><span><time datetime=\"2025-01-11\">11 January 2025</time></span></p></li><li><p>Published<span>: </span><span><time datetime=\"2025-01-22\">22 January 2025</time></span></p></li><li><p>DOI</abbr><span>: </span><span>https://doi.org/10.1186/s13054-025-05271-4</span></p></li></ul><h3>Share this article</h3><p>Anyone you share the following link with will be able to read this content:</p><button data-track=\"click\" data-track-action=\"get shareable link\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Get shareable link</button><p>Sorry, a shareable link is not currently available for this article.</p><p data-track=\"click\" data-track-action=\"select share url\" data-track-label=\"button\"></p><button data-track=\"click\" data-track-action=\"copy share url\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Copy to clipboard</button><p> Provided by the Springer Nature SharedIt content-sharing initiative </p>","PeriodicalId":10811,"journal":{"name":"Critical Care","volume":"74 1","pages":""},"PeriodicalIF":8.8000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Renal replacement therapy in ICU: from conservative to restrictive strategy\",\"authors\":\"Khalil Chaïbi, Didier Dreyfuss, Stéphane Gaudry\",\"doi\":\"10.1186/s13054-025-05271-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Renal replacement therapy (RRT) is a cornerstone of the management of severe acute kidney injury (AKI) in critically ill patients. Despite being life-saving in several instances, RRT may be associated with significant complications, including bleeding, hemodynamic instability, infections, thrombosis, and possibly delayed renal recovery. Large randomized controlled trials (RCTs) have demonstrated that delaying RRT initiation, in the absence of life-threatening complications (conservative RRT strategy) allows 38% to 49% of patients to avoid RRT. In addition to reducing unnecessary treatment, this conservative approach may help protect kidney function [1,2,3]. Once RRT is initiated, intensivists usually prescribe a recommended (or standard) dose of RRT (a KT/V of 3.9 per week when using intermittent hemodialysis or extended RRT; an effluent volume of 20–25 ml/kg/h for continuous RRT) [4]. This ensures the efficacy of metabolic control but there remains significant uncertainty about how long RRT should be continued. In daily clinical practice, empirical criteria (i.e. increased urine output or decreased blood urea nitrogen) are used to guide RRT weaning. Current guidelines offer indeed little guidance on how to manage this process.</p><p>Given the safety of a conservative RRT initiation strategy, we suggest extending this concept to a new approach (called restrictive RRT strategy) that could potentially solve the hot topic questions of RRT dosing and RRT weaning. This approach would consist in the suspension of RRT after 3 days. At this moment, metabolic abnormalities that mandated RRT initiation would no longer be present and the cause of AKI would be, in most cases, treated (for instance by controlling sepsis or hemorrhage). Then the question would be the same as before the initiation of the first RRT session i.e., does the situation require starting RRT or can it be delayed until a conservative RRT initiation criterion is observed again? If RRT is resumed, the patient will receive a new RRT session, after which RRT will again be suspended. This targeted approach applied until renal recovery-would ensure the use of RRT only when truly necessary rather than its prolongation for vague reasons. The restrictive strategy differs from ongoing studies that investigate the intensity of each RRT session (only for continuous RRT modality) (NCT06446739, NCT06014801, NCT06021288). Indeed, a restrictive approach would not diminish the intensity of each session, well the contrary, but the number of sessions by suspending pending a new indication for resumption occurs. Although this approach presents methodological challenges, we believe it is essential to evaluate it regardless of the initial RRT modality—intermittent (IHD) or continuous (CRRT)—since neither has shown definitive superiority.</p><p>The potential benefits of a restrictive RRT strategy for patients are numerous. By reducing unnecessary RRT exposure, patients could experience fewer episodes of hemodynamic instability, a common complication during RRT sessions, and a lower risk of infections, particularly those related to RRT catheters. Additionally, minimizing RRT may promote faster renal recovery by avoiding the \\\"second hit\\\" that RRT can impose on the kidneys [1, 5]. Fewer RRT sessions would make general patient management such as physiotherapy or transport easier. Patients might also experience better sleep quality, as RRT machines and alarms are a frequent source of disturbances improving the overall ICU environment. Moreover, RRT is a resource-intensive procedure, and minimizing its use would reduce both costs and the carbon footprint of critical care, in an era of increasing attention to healthcare sustainability [6].</p><p>On the other hand, shortening RRT sessions often raises concerns about achieving an adequate dose. Yet more intensive therapy does not necessarily translate into better outcomes in the ICU. Large RCTs have shown no mortality advantage for high-dose RRT regimens [7, 8], and recent meta-analyses even suggest that higher-intensity therapy may delay renal recovery [9]. Notably, the three above mentioned ongoing trials of low-dose CRRT demonstrate that the concept of a lower-dose intervention is considered sufficiently acceptable to be rigorously tested—thus challenging the assumption that less intensive dialysis automatically means unsafe underdialysis. However, these trials still focus on fixed-dose CRRT rather than a truly individualized approach and do not aim at reducing the number of sessions nor determining the moment for cessation. By contrast, by centering on individual patient needs, the restrictive strategy we propose aligns more closely with the ultimate goal of personalized medicine—an essential objective in modern critical care.</p><p>As we reconsider how to best use RRT, a more selective, needs-based approach could be the key to optimizing care. We are currently applying for a grant from the French Ministry of Health to conduct an RCT to evaluate this restrictive RRT strategy, focusing on a tailored approach providing no more than what is warranted.</p><p>No datasets were generated or analysed during the current study.</p><dl><dt style=\\\"min-width:50px;\\\"><dfn>RRT:</dfn></dt><dd>\\n<p>Renal replacement therapy</p>\\n</dd><dt style=\\\"min-width:50px;\\\"><dfn>AKI:</dfn></dt><dd>\\n<p>Acute kidney injury</p>\\n</dd><dt style=\\\"min-width:50px;\\\"><dfn>RCT:</dfn></dt><dd>\\n<p>Randomized controlled trials</p>\\n</dd></dl><ol data-track-component=\\\"outbound reference\\\" data-track-context=\\\"references section\\\"><li data-counter=\\\"1.\\\"><p>Benichou N, Gaudry S, Dreyfuss D. The artificial kidney induces acute kidney injury: yes. Intensive Care Med. 2020;46(3):513–5.</p><p>Article CAS PubMed Google Scholar </p></li><li data-counter=\\\"2.\\\"><p>STARRT-AKI Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Canadian Nephrology Trials Network, Irish Critical Care Trials Group, et al. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med. 2020;383:240–51.</p></li><li data-counter=\\\"3.\\\"><p>Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375:122–33.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\\\"4.\\\"><p>Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–84.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\\\"5.\\\"><p>Vanmassenhove J, Kielstein J, Jörres A, Biesen WV. Management of patients at risk of acute kidney injury. Lancet. 2017;389:2139–51.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\\\"6.\\\"><p>Stigant CE, Barraclough KA, Harber M, Kanagasundaram NS, Malik C, Jha V, et al. Our shared responsibility: the urgent necessity of global environmentally sustainable kidney care. Kidney Int. 2023;104:12–5.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\\\"7.\\\"><p>Network TVARFT. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20.</p><p>Article Google Scholar </p></li><li data-counter=\\\"8.\\\"><p>RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009;361:1627–38.</p><p>Article Google Scholar </p></li><li data-counter=\\\"9.\\\"><p>Wang Y, Gallagher M, Li Q, Lo S, Cass A, Finfer S, et al. Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: a systematic review and individual patient data meta-analysis. Nephrol Dial Transplant. 2018;33:1017–24.</p><p>PubMed Google Scholar </p></li></ol><p>Download references<svg aria-hidden=\\\"true\\\" focusable=\\\"false\\\" height=\\\"16\\\" role=\\\"img\\\" width=\\\"16\\\"><use xlink:href=\\\"#icon-eds-i-download-medium\\\" xmlns:xlink=\\\"http://www.w3.org/1999/xlink\\\"></use></svg></p><p>Not applicable</p><p>Not applicable.</p><span>Author notes</span><ol><li><p>Stéphane Gaudry</p><p>Present address: Intensive Care Unit, Hôpital Avicenne, 125 Rue de Stalingrad, 93000, Bobigny, France</p></li></ol><h3>Authors and Affiliations</h3><ol><li><p>Département de Réanimation Médico-Chirurgicale, APHP Hôpital Avicenne, 125 Rue de Stalingrad, 93000, Bobigny, France</p><p>Khalil Chaïbi & Stéphane Gaudry</p></li><li><p>Common and Rare Kidney Diseases: from Molecular Events to Precision Medicine, CoRaKiD, Sorbonne Université, INSERM, 75020, Paris, France</p><p>Khalil Chaïbi, Didier Dreyfuss & Stéphane Gaudry</p></li><li><p>Médecine Intensive-Réanimation, APHP, Hôpital Louis Mourier, Université Paris Cité, Colombes, France</p><p>Didier Dreyfuss</p></li><li><p>Health Care Simulation Center, UFR SMBH, Université Sorbonne Paris Nord, Bobigny, France</p><p>Stéphane Gaudry</p></li></ol><span>Authors</span><ol><li><span>Khalil Chaïbi</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Didier Dreyfuss</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Stéphane Gaudry</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Contributions</h3><p>KC, DD and SG drafted the manuscript.</p><h3>Corresponding author</h3><p>Correspondence to Stéphane Gaudry.</p><h3>Ethics approval and consent to participate</h3>\\n<p>Not applicable.</p>\\n<h3>Consent for publication</h3>\\n<p>Not applicable.</p>\\n<h3>Competing interests</h3>\\n<p>The authors declare no competing interests.</p><h3>Publisher's Note</h3><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p><p><b>Open Access</b> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.</p>\\n<p>Reprints and permissions</p><img alt=\\\"Check for updates. Verify currency and authenticity via CrossMark\\\" height=\\\"81\\\" loading=\\\"lazy\\\" src=\\\"data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\\\" width=\\\"57\\\"/><h3>Cite this article</h3><p>Chaïbi, K., Dreyfuss, D. & Gaudry, S. Renal replacement therapy in ICU: from conservative to restrictive strategy. <i>Crit Care</i> <b>29</b>, 40 (2025). https://doi.org/10.1186/s13054-025-05271-4</p><p>Download citation<svg aria-hidden=\\\"true\\\" focusable=\\\"false\\\" height=\\\"16\\\" role=\\\"img\\\" width=\\\"16\\\"><use xlink:href=\\\"#icon-eds-i-download-medium\\\" xmlns:xlink=\\\"http://www.w3.org/1999/xlink\\\"></use></svg></p><ul data-test=\\\"publication-history\\\"><li><p>Received<span>: </span><span><time datetime=\\\"2024-11-26\\\">26 November 2024</time></span></p></li><li><p>Accepted<span>: </span><span><time datetime=\\\"2025-01-11\\\">11 January 2025</time></span></p></li><li><p>Published<span>: </span><span><time datetime=\\\"2025-01-22\\\">22 January 2025</time></span></p></li><li><p>DOI</abbr><span>: </span><span>https://doi.org/10.1186/s13054-025-05271-4</span></p></li></ul><h3>Share this article</h3><p>Anyone you share the following link with will be able to read this content:</p><button data-track=\\\"click\\\" data-track-action=\\\"get shareable link\\\" data-track-external=\\\"\\\" data-track-label=\\\"button\\\" type=\\\"button\\\">Get shareable link</button><p>Sorry, a shareable link is not currently available for this article.</p><p data-track=\\\"click\\\" data-track-action=\\\"select share url\\\" data-track-label=\\\"button\\\"></p><button data-track=\\\"click\\\" data-track-action=\\\"copy share url\\\" data-track-external=\\\"\\\" data-track-label=\\\"button\\\" type=\\\"button\\\">Copy to clipboard</button><p> Provided by the Springer Nature SharedIt content-sharing initiative </p>\",\"PeriodicalId\":10811,\"journal\":{\"name\":\"Critical Care\",\"volume\":\"74 1\",\"pages\":\"\"},\"PeriodicalIF\":8.8000,\"publicationDate\":\"2025-01-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13054-025-05271-4\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13054-025-05271-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
Renal replacement therapy in ICU: from conservative to restrictive strategy
Renal replacement therapy (RRT) is a cornerstone of the management of severe acute kidney injury (AKI) in critically ill patients. Despite being life-saving in several instances, RRT may be associated with significant complications, including bleeding, hemodynamic instability, infections, thrombosis, and possibly delayed renal recovery. Large randomized controlled trials (RCTs) have demonstrated that delaying RRT initiation, in the absence of life-threatening complications (conservative RRT strategy) allows 38% to 49% of patients to avoid RRT. In addition to reducing unnecessary treatment, this conservative approach may help protect kidney function [1,2,3]. Once RRT is initiated, intensivists usually prescribe a recommended (or standard) dose of RRT (a KT/V of 3.9 per week when using intermittent hemodialysis or extended RRT; an effluent volume of 20–25 ml/kg/h for continuous RRT) [4]. This ensures the efficacy of metabolic control but there remains significant uncertainty about how long RRT should be continued. In daily clinical practice, empirical criteria (i.e. increased urine output or decreased blood urea nitrogen) are used to guide RRT weaning. Current guidelines offer indeed little guidance on how to manage this process.
Given the safety of a conservative RRT initiation strategy, we suggest extending this concept to a new approach (called restrictive RRT strategy) that could potentially solve the hot topic questions of RRT dosing and RRT weaning. This approach would consist in the suspension of RRT after 3 days. At this moment, metabolic abnormalities that mandated RRT initiation would no longer be present and the cause of AKI would be, in most cases, treated (for instance by controlling sepsis or hemorrhage). Then the question would be the same as before the initiation of the first RRT session i.e., does the situation require starting RRT or can it be delayed until a conservative RRT initiation criterion is observed again? If RRT is resumed, the patient will receive a new RRT session, after which RRT will again be suspended. This targeted approach applied until renal recovery-would ensure the use of RRT only when truly necessary rather than its prolongation for vague reasons. The restrictive strategy differs from ongoing studies that investigate the intensity of each RRT session (only for continuous RRT modality) (NCT06446739, NCT06014801, NCT06021288). Indeed, a restrictive approach would not diminish the intensity of each session, well the contrary, but the number of sessions by suspending pending a new indication for resumption occurs. Although this approach presents methodological challenges, we believe it is essential to evaluate it regardless of the initial RRT modality—intermittent (IHD) or continuous (CRRT)—since neither has shown definitive superiority.
The potential benefits of a restrictive RRT strategy for patients are numerous. By reducing unnecessary RRT exposure, patients could experience fewer episodes of hemodynamic instability, a common complication during RRT sessions, and a lower risk of infections, particularly those related to RRT catheters. Additionally, minimizing RRT may promote faster renal recovery by avoiding the "second hit" that RRT can impose on the kidneys [1, 5]. Fewer RRT sessions would make general patient management such as physiotherapy or transport easier. Patients might also experience better sleep quality, as RRT machines and alarms are a frequent source of disturbances improving the overall ICU environment. Moreover, RRT is a resource-intensive procedure, and minimizing its use would reduce both costs and the carbon footprint of critical care, in an era of increasing attention to healthcare sustainability [6].
On the other hand, shortening RRT sessions often raises concerns about achieving an adequate dose. Yet more intensive therapy does not necessarily translate into better outcomes in the ICU. Large RCTs have shown no mortality advantage for high-dose RRT regimens [7, 8], and recent meta-analyses even suggest that higher-intensity therapy may delay renal recovery [9]. Notably, the three above mentioned ongoing trials of low-dose CRRT demonstrate that the concept of a lower-dose intervention is considered sufficiently acceptable to be rigorously tested—thus challenging the assumption that less intensive dialysis automatically means unsafe underdialysis. However, these trials still focus on fixed-dose CRRT rather than a truly individualized approach and do not aim at reducing the number of sessions nor determining the moment for cessation. By contrast, by centering on individual patient needs, the restrictive strategy we propose aligns more closely with the ultimate goal of personalized medicine—an essential objective in modern critical care.
As we reconsider how to best use RRT, a more selective, needs-based approach could be the key to optimizing care. We are currently applying for a grant from the French Ministry of Health to conduct an RCT to evaluate this restrictive RRT strategy, focusing on a tailored approach providing no more than what is warranted.
No datasets were generated or analysed during the current study.
RRT:
Renal replacement therapy
AKI:
Acute kidney injury
RCT:
Randomized controlled trials
Benichou N, Gaudry S, Dreyfuss D. The artificial kidney induces acute kidney injury: yes. Intensive Care Med. 2020;46(3):513–5.
Article CAS PubMed Google Scholar
STARRT-AKI Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Canadian Nephrology Trials Network, Irish Critical Care Trials Group, et al. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med. 2020;383:240–51.
Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375:122–33.
Article PubMed Google Scholar
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–84.
Article PubMed Google Scholar
Vanmassenhove J, Kielstein J, Jörres A, Biesen WV. Management of patients at risk of acute kidney injury. Lancet. 2017;389:2139–51.
Article PubMed Google Scholar
Stigant CE, Barraclough KA, Harber M, Kanagasundaram NS, Malik C, Jha V, et al. Our shared responsibility: the urgent necessity of global environmentally sustainable kidney care. Kidney Int. 2023;104:12–5.
Article PubMed Google Scholar
Network TVARFT. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20.
Article Google Scholar
RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009;361:1627–38.
Article Google Scholar
Wang Y, Gallagher M, Li Q, Lo S, Cass A, Finfer S, et al. Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: a systematic review and individual patient data meta-analysis. Nephrol Dial Transplant. 2018;33:1017–24.
PubMed Google Scholar
Download references
Not applicable
Not applicable.
Author notes
Stéphane Gaudry
Present address: Intensive Care Unit, Hôpital Avicenne, 125 Rue de Stalingrad, 93000, Bobigny, France
Authors and Affiliations
Département de Réanimation Médico-Chirurgicale, APHP Hôpital Avicenne, 125 Rue de Stalingrad, 93000, Bobigny, France
Khalil Chaïbi & Stéphane Gaudry
Common and Rare Kidney Diseases: from Molecular Events to Precision Medicine, CoRaKiD, Sorbonne Université, INSERM, 75020, Paris, France
Khalil Chaïbi, Didier Dreyfuss & Stéphane Gaudry
Médecine Intensive-Réanimation, APHP, Hôpital Louis Mourier, Université Paris Cité, Colombes, France
Didier Dreyfuss
Health Care Simulation Center, UFR SMBH, Université Sorbonne Paris Nord, Bobigny, France
Stéphane Gaudry
Authors
Khalil ChaïbiView author publications
You can also search for this author in PubMedGoogle Scholar
Didier DreyfussView author publications
You can also search for this author in PubMedGoogle Scholar
Stéphane GaudryView author publications
You can also search for this author in PubMedGoogle Scholar
Contributions
KC, DD and SG drafted the manuscript.
Corresponding author
Correspondence to Stéphane Gaudry.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Reprints and permissions
Cite this article
Chaïbi, K., Dreyfuss, D. & Gaudry, S. Renal replacement therapy in ICU: from conservative to restrictive strategy. Crit Care29, 40 (2025). https://doi.org/10.1186/s13054-025-05271-4
Download citation
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13054-025-05271-4
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
期刊介绍:
Critical Care is an esteemed international medical journal that undergoes a rigorous peer-review process to maintain its high quality standards. Its primary objective is to enhance the healthcare services offered to critically ill patients. To achieve this, the journal focuses on gathering, exchanging, disseminating, and endorsing evidence-based information that is highly relevant to intensivists. By doing so, Critical Care seeks to provide a thorough and inclusive examination of the intensive care field.